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Urine-sample-derived human induced pluripotent stem cells as a
model to study PCSK9-mediated autosomal dominant
hypercholesterolemia
Karim Si-Tayeb1,2,3,*,‡, Salam Idriss1,2,3,*, Benoite Champon1,2,3, Amandine Caillaud1,2,3, Matthieu Pichelin1,2,3,4,
Lucie Arnaud1,2,3, Patricia Lemarchand1,2,3, Cédric Le May1,2,3, Kazem Zibara5 and Bertrand Cariou1,2,3,4
ABSTRACT
Proprotein convertase subtilisin kexin type 9 (PCSK9) is
a critical modulator of cholesterol homeostasis. Whereas
PCSK9 gain-of-function (GOF) mutations are associated with
autosomal dominant hypercholesterolemia (ADH) and premature
atherosclerosis, PCSK9 loss-of-function (LOF) mutations have a
cardio-protective effect and in some cases can lead to familial
hypobetalipoproteinemia (FHBL). However, limitations of the
currently available cellular models preclude deciphering the
consequences of PCSK9 mutation further. We aimed to validate
urine-sample-derived human induced pluripotent stem cells
(UhiPSCs) as an appropriate tool to model PCSK9-mediated
ADH and FHBL. To achieve our goal, urine-sample-derived
somatic cells were reprogrammed into hiPSCs by using episomal
vectors. UhiPSC were efficiently differentiated into hepatocyte-like
cells (HLCs). Compared to control cells, cells originally derived
from an individual with ADH (HLC-S127R) secreted less PCSK9 in
the media (−38.5%; P=0.038) and had a 71% decrease (P<0.001)
of low-density lipoprotein (LDL) uptake, whereas cells originally
derived from an individual with FHBL (HLC-R104C/V114A)
displayed a strong decrease in PCSK9 secretion (−89.7%;
P<0.001) and had a 106% increase (P=0.0104) of LDL uptake.
Pravastatin treatment significantly enhanced LDL receptor (LDLR)
and PCSK9 mRNA gene expression, as well as PCSK9 secretion
and LDL uptake in both control and S127R HLCs. Pravastatin
treatment of multiple clones led to an average increase of LDL
uptake of 2.19±0.77-fold in HLC-S127R compared to 1.38±0.49
fold in control HLCs (P<0.01), in line with the good response
to statin treatment of individuals carrying the S127R mutation
(mean LDL cholesterol reduction=60.4%, n=5). In conclusion,
urine samples provide an attractive and convenient source of
somatic cells for reprogramming and hepatocyte differentiation,
but also a powerful tool to further decipher PCSK9 mutations and
function.
KEY WORDS: Urine-derived somatic cells, Human induced
pluripotent stem cells, Hepatocyte differentiation, Autosomal
dominant hypercholesterolemia, PCSK9
INTRODUCTION
Proprotein convertase subtilisin kexin type 9 (PCSK9) has been
identified as a major regulator of cholesterol homeostasis (Costet
et al., 2008; Seidah et al., 2003; Seidah et al., 2014). PCSK9 is
subjected to an intracellular autocleavage before being secreted by
the liver into the plasma, where it acts as an endogenous inhibitor of
the low-density lipoprotein (LDL) receptor (LDLR). PCSK9 binds
the extracellular epidermal growth factor-like repeat A (EGF-A)
domain of the LDLR and thus disrupts its recycling to the cell
surface by targeting it to the lysosomal pathway for degradation
(Seidah et al., 2014). In their seminal paper, Abifadel and
colleagues demonstrated that a PCSK9 gain-of-function (GOF)
mutation is the third most common cause of autosomal dominant
hypercholesterolemia (ADH), a genetic disease associated with
premature atherosclerosis (Abifadel et al., 2003). Thereafter, whole-
life lower concentrations of plasma LDL-cholesterol (LDL-C) and
protection against cardiovascular diseases were associated with
PCSK9 loss-of-function (LOF) mutations (Cohen et al., 2006). In
some cases, PCSK9 LOF mutations can lead to familial
hypobetalipoproteinemia (FHBL) (Cariou et al., 2009; Zhou
et al., 2012). Thus, lowering levels of LDL-C through PCSK9
inhibition together with statins has been considered as an attractive
and promising pharmaceutical approach (Cariou et al., 2011;
Farnier, 2013). In order to reach this goal, human monoclonal
antibodies (mAbs) directed against PCSK9 were developed for
clinical applications and recent Phase 3 trials showed a strong
reduction (up to 60%) of plasma LDL-C concentrations in various
hypercholesterolemic patients treated with anti-PCSK9 mAb (Blom
et al., 2014; Cannon et al., 2015; Cariou et al., 2011; Farnier, 2013;
Roth and Diller, 2014).
To date, current cellular models that are available to decipher
PCSK9 functions are limited to heterologous cell lines or hepatoma
cells with forced PCSK9 expression that are not suitable to clearly
describe the intracellular action of PCSK9. Alternatively, the
physiological relevance of cultured human fibroblasts for studying
lipoprotein metabolism has recently been challenged (Sniderman
et al., 2013). Therefore, we propose that the use of human induced
pluripotent stem cells (hiPSCs) differentiated into hepatocyte-like
cells (HLCs) could provide an adapted cellular environment to
conduct such studies. Indeed, it has been shown that hiPSCs
generated from skin fibroblasts of an individual carrying mutations
in the LDLR gene and differentiated into HLCs were able to
recapitulate the features of ADH (Cayo et al., 2012; Si-Tayeb et al.,
2010). Here, we used a convenient source of patient-derived somaticReceived 9 July 2015; Accepted 22 October 2015
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cells isolated directly from their urine samples. Urine-derived
progenitor cell (Ucell) isolation and amplification (for a review, see
Gerbal-Chaloin et al., 2014), as well as their reprogramming into
hiPSCs (Xue et al., 2013; Zhou et al., 2012), has been previously
established. Our study reports for the first time the modeling of
PCSK9-mediated ADH and FHBL after hepatic differentiation of
hiPSCs reprogrammed from urine-derived somatic cells, therefore
establishing a new patient-related model to further decipher PCSK9
functions.
RESULTS
Urine sample as a source of human somatic cells
Ucells were isolated and amplified from urine samples of 38 donors
(healthy or with ADH or FHBL). After a week of culture, clusters of
Ucells displayed a ‘rice grain’ morphology with a high rate of
proliferation (Fig. 1A) in 67% of collected healthy donors or
patients, including those carrying the PCSK9-S127R (ADH) and
R104C/V114A (FHBL) mutations. As observed with bone-marrow-
and adipose-tissue-derived mesenchymal stromal cells (MSCs) by
flow cytometry, Ucells did not express the hematopoietic markers
CD14, CD45 and CD184, and expressed MSC markers CD49a,
CD73, CD90 and CD105 (Fig. 1B). We also noticed a higher
number of Ucells positive for the endothelial-cell-lineage marker
CD146 compared to MSCs. Finally, the ability of Ucells to perform
osteoblastic and chondrogenic differentiation was verified
(Fig. 1C). Control Ucells from a healthy female donor, PCSK9-
S127R Ucells from a female patient, initially described in the
seminal paper identifying PCSK9-mediated ADH (Abifadel et al.,
2003), and Ucells PCSK9-R104C/V114A from a male patient with
FHBL (Cariou et al., 2009) were used for subsequent experiments.
Generation and characterization of UhiPSCs
Ucells were reprogrammed upon transfection of factors encoded
by episomal vectors. Several stoichiometries were tested (Fig. S1)
to select the most efficient cocktail of reprogramming factors to
generate urine-sample-derived human induced pluripotent stem
cells (UhiPSCs). Several clones were obtained from control, S127R
and R104C/V114A Ucells, and three of each were used for
hepatocyte differentiation and characterization.
Control, PCSK9-S127R and PCSK9-R104C/V114A UhiPSCs
formed colonies with a morphology similar to that of human
embryonic stem cells on mouse embryonic fibroblasts (MEFs). They
expressed the pluripotency markers OCT3/4 and TRA1-60, as
assessed by immunofluorescence (Fig. 2A), as well as SOX2 and
NANOG, as assessed by quantitative reverse-transcriptase PCR (RT-
qPCR); the loss of episomal vectors was also verified (Fig. S2A).
Ucells and correspondingUhiPSCs shared the sameDNA fingerprint
(data not shown), and, compared to control cells, PCSK9-S127R and
PCSK9 R104C/V114A UhiPSCs retained their PCSK9 mutation
upon reprogramming (Fig. S2B). Under feeder-free conditions,
tested clones (control, PCSK9-S127R and PCSK9-R104C/V114A)
remained positive for the pluripotency markers SSEA4, SSEA3 and
TRA1-60 following flow cytometry analysis (Fig. 2B and Fig. S2C).
A transcriptomic analysis was performed and confirmed the global
gene-expression profile modification between two control Ucell
lines, two PCSK9-S127R Ucell lines and three clones of each
UhiPSC line generated (Fig. 2C). The injection of control and
PCSK9-S127R UhiPSCs into NOD Scid gamma (NSG) mice led to
the formation of teratomas that included differentiated tissues from all
three germ layers (Fig. 2D). Finally, although reprogrammed cells
displayed normal karyotypes (Fig. S3), trisomy (chromosomes 1, 14
or 21) occurred in some clones at late passages (above p65; data not
shown). Therefore, UhiPSCs between passage 25 and 40 were used
for further differentiation and functional analyses. Altogether, our
data support the successful reprogramming of Ucells.
UhiPSCs differentiate into hepatocyte-like cells
UhiPSCs were differentiated toward HLCs as a monolayer
under feeder-free conditions and completely defined medium.
Control (not shown), PCSK9-S127R and PCSK9-R104C/V114A
Fig. 1. Ucell characterization. (A) Urine-derived
progenitor cell (Ucell) morphology after isolation
and amplification. (B) Cell marker expression
analysis (percentage of positive cells) of Ucells,
bone-marrow-derived and adipose-tissue-derived
mesenchymal stem cells by flow cytometry.
(C) Osteoblastic and chondrogenic differentiation
of Ucells detected by Alizarin Red and Alcian Blue
staining, respectively. Scale bars: 100 µm.
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differentiated cells displayed human hepatocyte morphology and
co-expressed the hepatic markers FOXA2, AFP, HNF4α and
albumin, as seen by immunofluorescent staining (Fig. 3A). By
counting the albumin-positive cells, the differentiation efficiency
was evaluated to 84.9±7%, 92.7±1.2% and 91.4±4.8% for control,
PCSK9-S127R and PCSK9-R104C/V114A HLCs, respectively.
Gene expression levels of several hepatic genes, such as ALB,
HNF4a and SREBF2, as well as LDLR, were similar in control,
S127R and R104C/V114A HLCs. A slight, but significant,
reduction of PCSK9 mRNA level (41.9±31%; P=0.046) and a
reduction of HMGCR mRNA levels (46±4.2%; P=0.003) were
observed in S127R HLCs compared to control HLCs (Fig. 3B).
Differentiated UhiPSCs recapitulate the functional defects
of PCSK9-S127R and PCSK9-R104C/V114A mutations
Next, we aimed to demonstrate that UhiPSCs could serve
as an appropriate cellular model to study PCSK9 mutations. In
accordance with the inability of the mutated PCSK9 protein
encoded by the S127R allele to be secreted extracellularly
(Benjannet et al., 2004; Cameron et al., 2006), we found a 38.5%
reduction of PCSK9 secretion by PCSK9-S127R HLCs compared
to controls (Fig. 3C). In addition, a drastic 89.7% decreased level of
PCSK9 secretion was observed in R104C/V114A HLCs compared
to controls (Fig. 3C). This is in line with the dominant negative
effect exerted by R104C/V114A previously reported in vitro and the
absence of detectable circulating PCSK9 in the corresponding
affected individual (Cariou et al., 2009). In accordance with the
hypercholesterolemic phenotype of S127R carriers, HLC PCSK9-
S127R showed a 71% (±14%; P<0.001) decrease in their ability to
uptake LDL compared to HLC controls, as assessed by fluorescent
microscopy (Fig. S4) and by flow cytometry analysis (Fig. 3D). In
contrast, as expected with a LOF PCSK9 mutation, HLC PCSK9-
R104C/V114A displayed a 106% (±57%; P=0.0104) increase in
their ability to uptake LDL as compared to HLC control (Fig. 3E).
Fig. 2. UhiPSC characterization. (A) Detection of
OCT3/4 and Tra1-60 expression by fluorescent
immunostaining on control UhiPSCs and UhiPSCs
carrying the PCSK9-S127R or PCSK9-R104C/
V114A mutations. (B) Representative flow-cytometry
analysis for the detection of SSEA4, SSEA3 and
TRA1-60 expression by control (Ct) UhiPSCs.
(C) Global gene-expression profile comparison
between Ucell control (ct), Ucell S127R, UhiPSC
control and UhiPSCs carrying the PCSK9-S127R
mutation. (D) Hematoxylin- and eosin-stained
histological section of teratomas showing, from left to
right, ectoderm-derived neurons, mesoderm-derived
cartilage and endoderm-derived intestinal-like tissue
for UhiPSC-Control (Ct), and ectoderm-derived
retinal cells, mesodermal-derived bone tissue and
endodermal-derived exocrine pancreatic glands for
UhiPSC PCSK9-S127R. Scale bars: 100 µm.
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Fig. 3. See next page for legend.
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Our results demonstrated that HLCs differentiated from hiPSCs
derived from urine samples of individuals with PCSK9-mediated
ADH or FHBL reproduced the main PCSK9 pathological features
in vitro.
PCSK9-S127R HLCs displayed an increased response to
statin
In a final step, we investigated the effect of statins, the most widely
used hypolipidemic drugs in clinical practice. Statins act by
inhibiting 3-hydroxy-3-methyl glutaryl coenzyme A (CoA)
reductase (HMGCR), leading to reduced endogenous cholesterol
synthesis and subsequent upregulation of LDLRs through the
SREBP2 pathway. Control and PCSK9-S127R HLCs were treated
with pravastatin (10 µM) for 24 h, which did not affect the gene
expression of hepatic markers such as HNF4a and albumin
(Fig. 4A). Whereas SREBF2 expression was not modified by the
pravastatin treatment, because its regulation is mostly post-
transcriptional, a significant increase in SREBP2 target gene
expressions was observed, including HMGCR (control: 93±66%;
PCSK9-S127R: 53±16%), LDLR (control: 50±28%; PCSK9-
S127R: 21±11%) and PCSK9 (control: 185±95%; PCSK9-
S127R: 157±74%) (Fig. 4B). Correlated with these gene
expression data, an increase in PCSK9 secretion was observed by
Fig. 3. UhiPSC differentiation into HLCs. (A) Pictures of HLCs carrying the
S127R or R104C/V114A mutations. Left: HLC morphology observed by
brightfield microscopy (the lower panel represents a magnification of the upper
panel). Right: detection of the hepatic markers FOXA2, AFP, HNF4α and
albumin by fluorescent immunostaining (nuclei were stained in blue in merged
pictures). Scale bars: 100 µm. (B) Gene expression analysis by RT-qPCR of
albumin, HNF4a, SREBF2, LDLR, PCSK9 andHMGCR in control, S127R and
R104C/V114A HLCs (one clone per UhiPSC line; control n=6 differentiations,
PCSK9-S127R n=3 differentiations, PCSK9-R104C/V114A n=3
differentiations). (C) Secreted PCSK9 detection by ELISA assay (one clone
per UhiPSC line; control n=9 differentiations, PCSK9-S127R n=9
differentiations, PCSK9-R104C/V114A n=14 differentiations).
(D,E) Quantification by flow cytometry of incorporated LDL from HLCs
(D) PCSK9-S127R and (E) R104C/V114A compared to controls. MFI, mean
fluorescence intensity. *P<0.05, **P<0.01, ***P<0.001.
Fig. 4. Differentiated cell response to pravastatin
treatment. (A,B) Gene expression analysis by RT-qPCR of
albumin, HNF4a, SREBF2, LDLR, PCSK9 and HMGCR in
an untreated condition (black bars) and after 24 h of
pravastatin treatment at 10 µM (white bars) of control and
S127R HLCs (one clone per UhiPSC line; control n=6
differentiation, PCSK9-S127R n=3 differentiation).
(C) Secreted PCSK9 detection by ELISA assay (one clone
per UhiPSC line; control n=6 differentiations, PCSK9-
S127R n=6 differentiations). (D) Detection of incorporated
LDL by flow cytometry (one clone per UhiPSC line; control
n=6 differentiations, PCSK9-S127R n=3 differentiations).
MFI, mean fluorescence intensity. *P<0.05, **P<0.01.
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48.8±23% and 86.3±87% (Fig. 4C) and LDL uptake by 25.2±8%
and 352.9±137% (Fig. 4D) in control and S127R HLCs,
respectively. Similar results were observed upon lovastatin
(10 µM) treatment (data not shown). These results indicate that
UhiPSC-derived HLCs displayed all the characteristics necessary to
study PCSK9 functions in a suitable cellular environment. To
further validate these results, the same experiments were repeated in
two different additional clones of control and PCSK9-S127R
UhiPSCs. Compared to controls, HLC PCSK9-S127R displayed
non-significant enhanced expression of SREPF2, HMGCR, PCSK9
and LDLR mRNA levels under pravastatin treatment (Fig. 5A). In
addition, the induction of PCSK9 secretion upon statin treatment
was more pronounced in HLC S127R than in controls (Fig. 5B).
Finally, the statin-induced LDL uptake in HLCs carrying the
PCSK9-S127R mutation was significantly higher than in control
HLCs [2.19±0.77-fold (n=20) vs 1.38±0.49-fold (n=26),
respectively; P<0.01] (Fig. 5C).
Although unexpected, our results indicated that the PCSK9-
S127R mutation was associated with an enhanced response to
statins in vitro in HLCs.
Individuals carrying the S127R mutation are good
responders to statins
In order to validate the clinical relevance of these in vitro results
obtained in HLCs, we investigated the initial response to statin
therapy in five female patients with ADH related to S127R
mutations. As shown in Table 1, the mean decrease of LDL-C
following statin treatment was 60.4% [confidence interval (CI):−56
to −64%]. Amongst these patients, 3/5 were under a high dose of
statins (i.e. rosuvastatin 20 mg once daily). These data clearly
indicate that individuals with S127R mutations are good responders
to statin therapy, strengthening the usefulness of UhiPSC-derived
HLCs to model PCSK9-mediated ADH.
DISCUSSION
This study not only highlights the usefulness of urine samples as a
convenient source of patient-derived somatic cells to generate
UhiPSCs, but also demonstrates their potential, when differentiated
into HLCs, to model human metabolic diseases, such as ADH.
Notably, we demonstrated for the first time that HLCs are a unique
tool to study PCSK9 biology. Here, we specifically studied the
seminal PCSK9-S127R GOF mutation that allowed the
identification of PCSK9 as the third gene of ADH in a large
French family in 2003 (Abifadel et al., 2003).
The S127R mutation is one of the most intriguing PCSK9 ones,
which, despite its inability to be secreted in the extracellular space,
provokes ADH, suggesting an intracellular role of PCSK9
(Benjannet et al., 2004; Pandit et al., 2008). Compared to the
D374Y GOF mutation, which strengthens the affinity between
PCSK9 and LDLR, the S127R mutation does not affect PCSK9
binding to LDLR (Pandit et al., 2008). It has been suggested that the
S127R mutation might either enhance the ability of PCSK9 to bind
LDLR after cellular uptake or might act intracellularly to redirect
LDLR to the lysosomes for degradation. However, it is important to
note that discrepant data have been reported concerning the impact
of S127R mutation on the amount of cell surface LDLR and/or
internalization rate of LDL by LDLR. On one hand, reduced
amounts of LDLR and decreased internalization of LDL have been
described in HepG2 cells stably transfected with S127R when
compared with wild-type (WT)-PCSK9 (Benjannet et al., 2004). On
the other hand, the overexpression of S127R and WT-PCSK9 in
HepG2 cells or in mouse livers using adenoviruses did not lead to
statistical differences in regards to the amount of LDLR (Park et al.,
2004). In addition, the McArdle RH7777 hepatoma cell line stably
expressing PCSK9-S127R constructs failed to show a significant
reduction of the amount of LDLR when compared to those
expressing WT-PCSK9 (Sun et al., 2005).
Fig. 5. Comparative analysis of the response of control and
PCSK9-S127R HLCs to pravastatin treatment, normalized
to untreated conditions. (A) Gene expression analysis by
RT-qPCR of SREBF2, LDLR, PCSK9 and HMGCR (three
clones per UhiPSC line; n=3 differentiations per clone).
(B) Secreted PCSK9 detected by ELISA assay (one clone per
UhiPSC line; n=9 differentiations per clone). (C) Detection of
incorporated LDL by flow cytometry (three clones per UhiPSC
line; n=3 differentiations per clone). **P<0.01.
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Our data suggested that less PCSK9 was secreted from S127R
compared to control HLCs, in accordance with a defect in PCSK9
maturation and processing. However, this observation has been
made from multiple differentiations of a single UhiPSC clone
generated from one individual carrying the PCSK9-S127R GOF
mutation, and suffered from a lack of statistical robustness
(P=0.038). Therefore, PCSK9 secretion must be evaluated from
HLCs obtained from multiple donors carrying the PCSK9-S127R
mutation in order to strengthen and confirm our data. Importantly,
the ability of HLC S127R to internalize LDL is severely reduced by
71% compared to control cells, validating the hypothesis of an
additional intracellular pathway for the regulation of LDLR
trafficking by PCSK9. Our results obtained with UhiPSC-derived
HLCs confirmed those observed in lymphoblasts of individuals
with the S127R mutation, in which the cell surface LDLR levels are
reduced by 35% (Benjannet et al., 2004). In contrast, in HepG2 cells
transfected with PCSK9-S127R plasmid, only a 7% reduction in the
amount of LDL internalized is observed when compared with WT-
PCSK9 (Cameron et al., 2006). It could be reasonably hypothesized
that endogenous partners and/or regulators of PCSK9 are expressed
in a more physiological stoichiometry in HLCs than in lymphoblasts
or transfected hepatoma cell lines. Furthermore, although the use of
lymphoblasts seems attractive because of their ease to be generated
compared to differentiated UhiPSCs, it has been reported that the
expression level of PCSK9 in lymphocytes is less than 1/1000 of the
level reported in hepatocytes (Holla et al., 2006). The liver remains
the major organ involved in PCSK9 expression and secretion (Zaid
et al., 2008) and the regulation of the cholesterol metabolism. Thus,
investigating PCSK9 roles and functions in lipid disorders such as
ADH and FHBL would be more likely to be reliable if it is done in
the context of human-derived hepatocytes (i.e. HLCs).
Because control and mutated HLCs are coming from unrelated
donors, the different genetic background carried by the different
UhiPSCs could hamper our observations. Therefore, to further
validate our model, we generated UhiPSCs from an individual
carrying heterozygous LOF mutations R104C/V114A. Upon HLC
differentiation, and in line with previously published data (Cariou
et al., 2009), we observed a strong decrease in PCSK9 secretion
(89.7%) together with an increased LDL uptake (106%).
Altogether, our data strongly suggest that the phenotypes
observed with the use of our model are linked to PCSK9
mutations rather than genetic-background differences.
UhiPSC-derivedHLCs could serve as a valuable pharmacological
cell model because they respond normally to the hypolipidemic
drugs statins. As expected, statin treatment induces: (i) expression of
SREBP2 target genes such as LDLR and PCSK9; (ii) PCSK9
secretion; and (iii) LDL uptake. Unexpectedly, HLCs carrying the
S127R GOF mutation displayed a better response to statin, with a
more important increase of LDL uptake compared to control cells.
This finding was counterintuitive because both PCSK9-deficient
mice (Rashid et al., 2005) and individuals harboring PCSK9 LOF
mutations (Berge et al., 2006) have an increased response to statin
therapy. Importantly, our in vitro observations correlated with
clinical observations from individuals carrying the S127Rmutation,
who seem to be good responders to statins, with a mean decrease of
LDL-C by ≈60%. Usually, a reduction in serum LDL-C of 52% is
observed on rosuvastatin 20 mg and 38-40% on simvastatin 40 mg
in non-ADH patients (Jones et al., 1998, 2003). The underlying
molecular mechanisms of this increased sensitivity to statins related
to S127R mutation remain unknown, and need further
investigations. Although there was a tendency for an increase of
SREBF2 expression aswell as that of its main target genes,HMGCR,
PCSK9 and, to a lesser extent, LDLR, in S127R HLCs compared
with controls, it did not reach statistical significance. This result
could be due to a lack of statistical power, but we cannot exclude that
the S127R mutation might modulate LDLR expression
independently of SREBP2 signaling.
hiPSCs have already been used as a model for studying ADH
linked to LDLR mutations (Cayo et al., 2012; Idriss et al., 2015;
Rashid et al., 2010). Here, we showed for the first time that HLCs
differentiated from urine-derived hiPSCs are suitable to model ADH
related to a PCSK9 GOF mutation. The main advantages of urine
collections are their ease of use, the very low occurrence of
contamination (about 6%) and, in cases in which the first sample did
not successfully yield somatic cells or efficient reprogramming, it is
easier to obtain new urine samples compared with obtaining other
sources of somatic cells such as skin biopsies or blood samples.
More importantly, because it is a non-invasive method, it provides a
better acceptability by the patient compared to skin biopsies, and
seems to be suitable for accessing cells from pediatric patients with
minimal stress.
Conclusions
We demonstrated for the first time that UhiPSC-derived hepatocytes
are a valuable and reproducible human in vitro cellular model to
study PCSK9 biology. This model will certainly help to further
decipher the function of PCSK9 mutations, to identify or validate
new PCSK9 partners and to assess the role of PCSK9 in lipoprotein
(a) metabolism (Romagnuolo et al., 2015). Ultimately, such
UhiPSC-derived hepatocytes are a promising pharmacological
model to test new PCSK9 inhibitors or modulators such as the
novel Sirt1 activator SRT3025, which has been recently shown to
reduce PCSK9-mediated LDLR degradation (Miranda et al., 2015).
MATERIALS AND METHODS
Ethics statement
The study was conducted in compliance with current Good Clinical Practice
standards and in accordance with the principles set forth under the
Declaration of Helsinki (1989). Each subject entering the study agreed to
and signed an institutional-review-board-approved statement of informed
Table 1. Plasma LDL cholesterol (LDL-C) values before and after initiation of statin therapy in patients with ADH linked to the PCSK9-S127R
mutation
Patient number Sex Age (years) LDL-C before statin (mg/dl) LDL-C upon statin (mg/dl) % decrease Statin dose
1* F 58 308 110 −64 Rosuva 20 mg/day
2 F 45 265 116 −56 Rosuva 20 mg/day
3 F 54 350 152 −57 Simva 40 mg/day
5 F 44 250 103 −59 Rosuva 20 mg/day
6 F 65 340 129 −62 Rosuva 5 mg/day
Mean 302.6 122.0 −60.4
*Indicates the patient for whom urine samples were used to obtain UhiPSCs.
F, female.
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consent for the collection of urine samples (authorization number from the
French Ministry of Health: DC-2011-1399).
Ucell collection and culture
Urine samples were collected in a 250 ml bottle previously conditioned with
10% of RE/MC medium (see below) for storage (up to 24 h at 4°C) and
transported as previously described (Lang et al., 2013). RE/MC (1:1)
medium was prepared as described by Zhou et al. (2012) by mixing RE
medium (Renal epithelial cell growth medium SingleQuot kit supplement
and growth factors; Lonza) with MC (mesenchymal cell) medium prepared
separately. MC medium is composed of DMEM/high glucose medium
(Hyclone) supplemented with 10% (vol/vol) FBS (Hyclone), 1% (vol/vol)
GlutaMAX (Life Technologies), 1% (vol/vol) NEAA (Life Technologies),
100 U/ml penicillin (Life Technologies), 100 μg/ml streptomycin (Life
Technologies), 5 ng/ml bFGF2 (Miltenyi), 5 ng/ml PDGF-AB (Cell
Guidance Systems) and 5 ng/ml EGF (Peprotech). Ucells were isolated
from urine samples and cultured according to the procedure described in
Zhou et al. (2012) with slight modifications. Briefly, urine samples were
centrifuged 5 min at 1200 g and the pellet was washed with pre-warmed
DPBS (Gibco) containing 100 U/ml penicillin and 100 µg/ml streptomycin
(Gibco). Pellets were resuspended in 2 ml RE/MC proliferation medium and
cultured on 0.1%gelatin-coated six-well plates. Cells were incubated at 37°C
in normoxia (20%O2, 5% CO2) for 4-5 days without any change of medium
normoving.Ucellswere further passaged usingTrypLEExpress (Gibco) and
expanded in RE/MC medium with daily change of half of the media. Upon
amplification, Ucells were characterized and frozen (Biobanker, Zenoaq).
For Ucell characterization, expression of mesenchymal stem cells surface
markers (see Table S1) was measured using flow cytometry and their
capacity to differentiate into osteocytic and chondrocytic tissue was
evaluated as previously described (Bharadwaj et al., 2013).
Ucell reprogramming
Ucells were reprogrammed into UhiPSCs as follow. Briefly, 3×105 to 5×105
of fresh or frozen Ucells were nucleofected using the basic epithelial cells
Nucleofector Kit (Lonza) with episomal vectors coding for OCT4, SOX2,
KLF4, MYC, LIN28, NANOG and SV40LT (Addgene Cat# 20922, 20923,
20924, 20925 and 20927), and a non-episomal vector coding for miR302/
367 (System Biosciences Cat# TDH101PA-GP). Nucleofected Ucells were
cultured at 37°C under hypoxia conditions (4%O2, 5%CO2) for 7 days with
RE/MC medium then 14-21 days with TeSR-E7 medium (Stem Cell
Technologies). UhiPSC clones were manually picked and transferred onto
mitomycin-treated MEFs for further culture and amplification.
UhiPSC culture
UhiPSCs were cultured on MEFs in hiPS medium composed of DMEM-
F12 medium (Life Technologies) supplemented with 20% Knockout Serum
Replacer (Life Technologies), 0.5% L-Glutamine (Life Technologies)
supplemented with 0.14% 2-Mercaptoethanol (Sigma), 1% NEAA and
5 ng/ml of fibroblast growth factor 2 (FGF2; Miltenyi) under hypoxic
condition (4% O2, 5% CO2) and manually passed once a week. For feeder-
free culture conditions, UhiPSC colonies were manually dissected from
MEFs and plated onto plates coated with Matrigel (Corning; 0.05 mg/ml) in
mTSeR (Stem Cell Technologies) or StemMACS iPS-Brew medium
(Miltenyi). Passages were performed using the Gentle Cell Dissociation
Buffer (Stem Cell Technologies).
Teratoma formation
Undifferentiated UhiPSCs cultured onMEFs were mechanically dissociated
with EZ Passage tools (Life Technologies), resuspended in Matrigel
(2 mg/ml) and injected subcutaneously into NOD Scid gamma (NSG)
mice. Tumor samples were collected at 8-10 weeks, fixed in 4%
paraformaldehyde, embedded in paraffin, sectioned, and stained with
hematoxylin and eosin for analysis.
Karyotyping
UhiPSCs were grown on Matrigel until reaching a 70% confluence and
treated with 0.13 µg/ml Colcemid (Life Technologies). UhiPSCs were then
removed, washed and subjected to a hypotonic shock using 0.075 M KCl,
before fixation with a 3:1 mixture of methanol/acid acetic. Pellets were
washed and sent for analysis at Cell Guidance Systems (http://www.cellgs.
com/Shop/Services/Karyotyping.html).
UhiPSC hepatic differentiation
UhiPSCs from passage 25-40 were differentiated into HLCs (named
hepatocyte in figures) as previously described (DeLaForest et al., 2011;
Si-Tayeb et al., 2010). Briefly, UhiPSCs were plated in tissue-culture
plates previously coated with Matrigel at 0.05 mg/ml for 1 h, and cultured
in mTSeR or StemMACS iPS-Brew. Once cells reached 70-80%
confluence, differentiation was performed with RPMI 1640 (Life
Technologies) and B27 (Life Technologies) containing Activin A (AA;
Miltenyi), FGF2, bone morphogenetic protein 4 (BMP4; Miltenyi) and
hepatocyte growth factors (HGFs; Miltenyi) with the following sequence:
AA/BMP4/FGF2 (2 days); AA (3 days), BMP4/FGF2 (5 days) and HGF
(5 days). Cells were then incubated with Hepatocyte Culture Medium
(Lonza) supplemented with oncostatin M (Miltenyi) for 5 days. The
hepatic differentiation efficiency for each UhiPSC culture was determined
upon counting of albumin-positive cells compared to total cells from
multiple fields.
Immunostainings
Cultured cells were fixed with 4% paraformaldehyde for 30 min at room
temperature (RT), permeabilized with 0.5% Triton X-100 in PBS for 15 min
and blocked with 3% BSA in PBS for 30 min. Cells were incubated
overnight at 4°Cwith primary antibodies diluted in 1%BSA in PBS, washed
three times with PBS/BAS 1% and incubated with suitable secondary
antibodies for 1 h at RT together with DAPI. Antibody references and
dilutions are listed in Table S1. Immunostainings were examined using an
inverted epifluorescent microscope (Zeiss Axiovert 200M).
Flow cytometry
For flow-cytometry analysis, 105 cells in suspension for each condition were
washed three times with a FACS Buffer (PBS/BSA 0.1%) then incubated
with PE-labeled antibodies (see Table S1) for 30 min at 4°C in the dark and
further rinsed three times with FACS buffer. Data acquisition was performed
using FACSDiva software with an LSR II instrument (Becton Dickinson) or
the Accury C6 (Becton Dickinson).
Genomic sequencing
Genomic DNA was isolated using the NucleoSpin Tissue Purification Kit
(Macherey Nagel). The DNA fragment of exon2 PCSK9 for S127R
mutation sequencing was amplified by PCR using 100 ng of genomic DNA
and specific forward (5′-TGGTCCGCATTTGGTAACTT-3′) and reverse
(5′-CCCCTTCTGATTTTCAGCAAT-3′) primers. PCR products were then
sequenced using the AB3730 sequencer (Applied Biosystems).
Gene expression analysis
RNA samples were isolated by using the RNeasy Mini Kit (Qiagen).
Reverse transcription of 1 μg of RNA into cDNA was conducted using the
High-Capacity cDNA Reverse-Transcription Kit (Applied Biosystems).
Conditions were as follows: 10 min at 25°C, and then 2 h at 37°C.
Quantitative polymerase chain reaction (qPCR) studies were conducted in
triplicate by using the Brilliant III Ultra-Fast Master Mix with high ROX
(Agilent). Primers are listed in Table S2. Each qPCR included 2 s at 50°C,
10 s at 95°C followed by 40 cycles of 15 s at 95°C, and 60 s at 60°C. Cycle
threshold was calculated by using default settings for the real-time sequence
detection software (Applied Biosystems).
Episomal vector detection
RT-PCR reactions were conducted in triplicate by using the Mesagreen 2×
PCRMaster Mix for SYBR (Eurogentec). The following primers were used:
forward: 5′-GGCTCTCCCATGCATTCAAA-3′, reverse: 5′-GGCCCTC-
ACATTGCCAAA-3′, with DNA concentration at 5 ng/well. Conditions
were: 2 s at 90°C, followed by 40 cycles of 10 s at 95°C and 30 s at 60°C,
and finished by 60 s at 60°C. Cycle threshold was calculated by using
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default settings for the real-time sequence detection software (Applied
Biosystems).
Gene arrays
RNA samples were prepared and hybridized on Agilent Human Gene
Expression 8×60 K microarrays (Agilent Technologies, part number:
G4851A). Normalization procedures were performed using R statistical
software (http://www.r-project.org). The raw signals of all probes for all the
arrays were normalized against a virtual median array (median raw intensity
per row) using a local weighted scattered plot smoother analysis (LOWESS).
The data were filtered to remove probes with low intensity values. This
filtering is performed by sample category in order to keep the signature of
categories with a small sample size. A hierarchical clustering was computed
on median-gene-centered and log-transformed data using average linkage
and uncentered correlation distances with the Cluster program. Raw and
normalized data have been deposited in the Gene Expression Omnibus
(GEO) database (accession number to be confirmed).
ELISA assay
PCSK9 levels in conditioned medium were assayed in duplicates using a
commercially available quantitative sandwich ELISA assay following the
manufacturer’s instructions (Circulex CY-8079, CycLex Co.). Data were
presented as PCSK9 secretion during 24 h per well (of a six-well plate) of
differentiated cells.
LDL uptake assay
Hepatocytes were exposed for 3 h to 5 µg/ml dil-LDL (Life Technologies)
or 5 µg/ml of BODIPY-FL-LDL (Life Technologies) in HCMmedium. For
uptake measurement, hepatocytes were washed five times with PBS then
dissociated for 40 min in Gentle Cell Dissociation Reagent. Cells were
recovered in PBS and analyzed by flow cytometry using the FACSARIA III
(Becton Dickinson).
Statistical analysis
Data are expressed as mean±s.e.m. Significant differences between mean
values were determined with the Mann–Whitney U-test for comparison of
two groups or paired Student’s t-test if appropriate. For the cluster approach,
genes belonging to the same biological function or cell type are known to
exhibit correlated expression.We use hierarchical clustering to detect groups
of correlated genes supported by a statistical method (limma) to detect
differential expression among biological conditions.
This article is part of a subject collection on Model Systems in Drug Discovery: from
Bench to Patient. See related articles in this collection at http://dmm.biologists.org/
cgi/collection/drugdiscovery
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